Dermata Receives Approval From FDA For The Proprietary Name Xyngari For Its Phase 3 Acne Candidate

BenzingaDec 16 22:04

Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)".

BenzingaDec 7 04:59

Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement

BenzingaDec 3 22:06

8-K: Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

SECNov 15 00:27

10-Q: Q3 2024 Earnings Report

SECNov 14 11:32 · Announcements

Dermata Therapeutics Q3 EPS $(2.04) Beats $(2.64) Estimate

BenzingaNov 14 05:40